Search reports, ask a question, or jump to a page.
The problem
Intervention: Two RSV preventive therapies: prenatal RSV vaccine (RSVpreF) and long-acting monoclonal antibody for infants (nirsevimab)
Who it was tested with: Canadian expectant parents and parents of infants born in the past year (n=1,015; 49% expecting, 51% with recent births).
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree)." This documents parental intentions toward new products but provides no evidence of intervention effectiveness, safety outcomes, or actual implementation results.
This is a survey of stated intentions, not an evaluation of an implemented intervention. No comparison group or outcome measurement of actual uptake, efficacy, or safety outcomes. The study cannot determine if acceptability translates to actual vaccine uptake or clinical benefit.
Across countries and designs
1 study · 1 country
